Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5278122
Max Phase: Preclinical
Molecular Formula: C22H14F2N2O
Molecular Weight: 360.36
Associated Items:
ID: ALA5278122
Max Phase: Preclinical
Molecular Formula: C22H14F2N2O
Molecular Weight: 360.36
Associated Items:
Canonical SMILES: O=c1c2ccccc2nc(-c2ccccc2)n1/C=C/c1ccc(F)c(F)c1
Standard InChI: InChI=1S/C22H14F2N2O/c23-18-11-10-15(14-19(18)24)12-13-26-21(16-6-2-1-3-7-16)25-20-9-5-4-8-17(20)22(26)27/h1-14H/b13-12+
Standard InChI Key: HXBDDNAZPRUKJX-OUKQBFOZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 360.36 | Molecular Weight (Monoisotopic): 360.1074 | AlogP: 4.97 | #Rotatable Bonds: 3 |
Polar Surface Area: 34.89 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 3.75 | CX LogP: 5.24 | CX LogD: 5.24 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.52 | Np Likeness Score: -0.88 |
1. Alagarsamy V, Chitra K, Saravanan G, Solomon VR, Sulthana MT, Narendhar B.. (2018) An overview of quinazolines: Pharmacological significance and recent developments., 151 [PMID:29656203] [10.1016/j.ejmech.2018.03.076] |
Source(1):